ArticleBiomaterials2011
Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research trends of nanotechnology in coronary heart disease: a bibliometric analysis from 2012 to 2025.Frontiers in pharmacology · 2026Pooled it
- Dextran Sulfate Nanocarriers: Design, Strategies and Biomedical Applications.International journal of molecular sciences · 2022Review
- Magnetic resonance imaging of tumor-associated-macrophages (TAMs) with a nanoparticle contrast agent.RSC advances · 2022Article
- Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis.Frontiers in pharmacology · 2022Review
- Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Review
- Imaging Constructs: The Rise of Iron Oxide Nanoparticles.Molecules (Basel, Switzerland) · 2021Review
- Towards Photoswitchable Contrast Agents for Absolute 3D Temperature MR Imaging.Angewandte Chemie (International ed. in English) · 2021Article
- In vivo Cell Tracking Using Non-invasive Imaging of Iron Oxide-Based Particles with Particular Relevance for Stem Cell-Based Treatments of Neurological and Cardiac Disease.Molecular imaging and biology · 2020Review
- A novel gamma GLM approach to MRI relaxometry comparisons.Magnetic resonance in medicine · 2020Article
- Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- Effects of Nanoprobe Morphology on Cellular Binding and Inflammatory Responses: Hyaluronan-Conjugated Magnetic Nanoworms for Magnetic Resonance Imaging of Atherosclerotic Plaques.ACS applied materials & interfaces · 2018Article
- Article
- Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future Perspectives.International journal of molecular sciences · 2017Review
- Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- A pH-Responsive Drug-Delivery Platform Based on Glycol Chitosan-Coated Liposomes.Small (Weinheim an der Bergstrasse, Germany) · 2015Article
- Quantitative assessment of binding affinities for nanoparticles targeted to vulnerable plaque.Bioconjugate chemistry · 2015Article
- Molecular imaging of plaques in coronary arteries with PET and SPECT.Journal of geriatric cardiology : JGC · 2014Review
- CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging.Pharmaceutical research · 2014Article
- Multimodality PET/MRI agents targeted to activated macrophages.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014Article
- Molecular imaging of inflammation in atherosclerosis.Theranostics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In a number of literature reports iron oxide nanoparticles have been investigated for use in imaging atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages, which are critical in the process of atheroma initiation, propagation, and rupture. However, the uptake of these agents is non-specific; thus the labeling efficiency for plaques in vivo is not ideal. We have developed targeted agents to improve the efficiency for labeling macrophage-laden plaques. These probes are based on iron oxide nanoparticles coated with dextran sulfate, a ligand of macrophage scavenger receptor type A (SR-A). We have sulfated dextran-coated iron oxide nanoparticles (DIO) with sulfur trioxide, thereby targeting our nanoparticle imaging agents to SR-A. The sulfated DIO (SDIO) remained mono-dispersed and had an average hydrodynamic diameter of 62 nm, an r(1) relaxivity of 18.1 mM(-1) s(-1), and an r(2) relaxivity of 95.8 mM(-1) s(-1) (37 °C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic and specifically targeted to macrophages. In vivo MRI after intravenous injection of the contrast agent into an atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and 24 h post-injection of SDIO. No discernable signal decrease was seen at the control carotid and only mild signal loss was observed for the injured carotid post-injection of non-sulfated DIO, indicating preferential uptake of the SDIO particles at the site of atherosclerotic plaque. These results indicate that SDIO can facilitate MRI detection and diagnosis of vulnerable plaques in atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.